What happened with ARVN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Arvinas designs experimental medicines that use the body’s natural protein-disposal system to remove proteins that cause disease. Its proprietary PROTAC Discovery Engine supports this work. The company has no approved products and has never earned revenue from drug sales.
Pharmaceutical partners pay Arvinas for access to its technology and candidates and for research work, providing most of its revenue through collaborations and licensing. Pfizer shares development costs for vepdegestrant and has worldwide co-exclusive development and commercialization rights. Novartis holds the exclusive worldwide license for luxdegalutamide and controls its development and commercialization. These agreements bring upfront payments and potential payments when development, approval or sales milestones are reached; some also provide royalties if licensed drugs sell.
The business depends on partners, including Pfizer, Novartis and Genentech, continuing their programs, and on candidates succeeding in trials and obtaining regulatory approval. Arvinas and Pfizer plan to select a third party to commercialize vepdegestrant and potentially develop it further. Existing agreements also limit Arvinas’s freedom to develop or license drugs against certain targets already covered by partners’ exclusive rights.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Arvinas’s outlook hinges on partnered drug development and breast cancer competition, including privately held Menarini’s Orserdu, an important rival missing from this list.
Arvinas depends on Pfizer, a drug manufacturer and seller, for payments on licensed protein-degrader programs, shared vepdegestrant development costs and primary responsibility for its commercial manufacturing supply. Watch vepdegestrant’s development plan: Arvinas’s 2025 collaboration revenue rose mainly because cost estimates changed after two Phase 3 combination trials were removed, rather than because of drug sales.
Olema Pharmaceuticals’ palazestrant competes with Arvinas’s vepdegestrant for the market for metastatic breast cancer treatments directed at the estrogen receptor. Olema has no approved products or product-sales revenue; palazestrant’s clinical results are the news to watch for this rivalry.
Arvinas’s income from luxdegalutamide depends on Novartis, which holds exclusive worldwide rights to develop, manufacture and sell the drug and pays Arvinas upfront fees, milestones and potential sales royalties. Development progress already produced a $20 million milestone payment in 2025; further milestones and eventual worldwide sales are the relevant signals, not Novartis’s overall drug revenue.
Nurix Therapeutics competes with Arvinas in developing medicines that remove targeted proteins and licensing drug-discovery capabilities to pharmaceutical partners, including Pfizer. Nurix has no product-sales revenue, so its collaboration revenue—particularly payments from their shared partner Pfizer—offers a concrete view of pharmaceutical demand for this approach.
Kymera Therapeutics’ trial results help test the viability of the small-molecule protein-degrader approach that Arvinas also uses, although Kymera mainly focuses on immunology. Its trials targeting STAT6, IRF5 and IRAK4 are therefore evidence about the approach, rather than direct tests of Arvinas’s breast cancer market.
LeonaBio’s lasofoxifene competes with Arvinas’s vepdegestrant program for patients with ESR1-mutated metastatic breast cancer. LeonaBio has no approved drugs or drug-product revenue, making its ongoing registrational Phase 3 lasofoxifene trial the concrete development to watch.
AstraZeneca and Arvinas develop or market treatments competing for patients with ESR1-mutated metastatic breast cancer. For Arvinas, the relevant AstraZeneca news is progress and treatment uptake in this patient group, rather than sales across its broader cancer-drug portfolio.
Eli Lilly’s Inluriyo competes with Arvinas’s breast cancer program for patients with ESR1-mutated metastatic disease. Lilly develops, manufactures and sells medicines; uptake of Inluriyo in this patient group is the relevant competitive signal for Arvinas.
Revolution Medicines’ zoldonrasib and Arvinas’s clinical KRAS G12D program pursue cancers driven by the same mutation. Revolution develops targeted cancer medicines, so zoldonrasib’s efficacy and safety results are the concrete comparison to watch for Arvinas’s program.
Fed Interest Rate Decision
For Arvinas, the Fed’s policy rate matters because it can change what the company earns on its cash, cash equivalents and marketable securities, a source of interest income.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can increase interest earned on those holdings, adding income to support Arvinas’s research and development spending.
If it comes in below expectations
Lower rates can reduce interest earned on those holdings, leaving less income to help fund Arvinas’s research and development spending.
Arvinas, Inc earningsThis company
Arvinas has no product sales and relies on partner payments to fund research, so this report shows whether collaboration revenue is keeping pace with the cost of developing its medicines.
Read collaboration revenue alongside research spending and cash used in operations. Steady partner revenue, controlled spending and no widening operating cash outflow would show that collaborators are still helping fund research without accelerating cash use. Falling revenue or a larger outflow would mean a thinner funding cushion and greater pressure to raise money or scale back development.
